Genesee Capital Advisors LLC Invests $889,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

Genesee Capital Advisors LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 36,749 shares of the company's stock, valued at approximately $889,000.

Several other hedge funds have also added to or reduced their stakes in HIMS. Perigon Wealth Management LLC purchased a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $337,000. Pacer Advisors Inc. purchased a new position in Hims & Hers Health during the fourth quarter valued at $374,000. KBC Group NV boosted its holdings in Hims & Hers Health by 107.9% in the 4th quarter. KBC Group NV now owns 8,471 shares of the company's stock worth $205,000 after buying an additional 4,396 shares during the period. Raleigh Capital Management Inc. boosted its position in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 1,100 shares during the last quarter. Finally, SG Americas Securities LLC increased its stake in Hims & Hers Health by 44.0% in the 4th quarter. SG Americas Securities LLC now owns 104,422 shares of the company's stock worth $2,525,000 after acquiring an additional 31,915 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on HIMS. Bank of America lowered Hims & Hers Health from a "buy" rating to an "underperform" rating and decreased their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a "buy" rating in a report on Monday, January 6th. Piper Sandler raised their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a "neutral" rating in a report on Monday, January 6th. BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price target on the stock. Finally, TD Cowen restated a "buy" rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Hims & Hers Health has an average rating of "Hold" and a consensus target price of $25.13.

Hims & Hers Health Stock Up 0.9 %

Shares of HIMS traded up $0.27 during trading hours on Wednesday, reaching $31.81. The company's stock had a trading volume of 6,002,671 shares, compared to its average volume of 9,880,767. The firm has a market cap of $6.95 billion, a price-to-earnings ratio of 72.29 and a beta of 1.31. Hims & Hers Health, Inc. has a 1-year low of $8.51 and a 1-year high of $35.02. The company has a 50 day moving average of $28.77 and a two-hundred day moving average of $22.39.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same period in the previous year, the company posted ($0.04) earnings per share. The firm's revenue for the quarter was up 77.1% on a year-over-year basis. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 17,304 shares of the business's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $31.00, for a total transaction of $536,424.00. Following the completion of the transaction, the insider now owns 193,601 shares in the company, valued at approximately $6,001,631. The trade was a 8.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Andrew Dudum sold 33,513 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.38, for a total value of $1,118,663.94. Following the completion of the sale, the chief executive officer now owns 33,502 shares of the company's stock, valued at $1,118,296.76. This trade represents a 50.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,256,067 shares of company stock worth $34,459,485 over the last ninety days. Corporate insiders own 17.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.